These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 1078601)

  • 1. The reversal of methotrexate toxicity by thymidine with maintenance of antitumour effects.
    Tattersall MH; Brown B; Frei E
    Nature; 1975 Jan; 253(5488):198-200. PubMed ID: 1078601
    [No Abstract]   [Full Text] [Related]  

  • 2. Methotrexate-thymidine treatment of murine leukemia.
    Tattersall MH; Brown BL; Frei E
    Ann N Y Acad Sci; 1975 Aug; 255():261-5. PubMed ID: 1081356
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of allopurinol on the therapeutic efficacy of methotrexate.
    Grindey GB; Moran RG
    Cancer Res; 1975 Jul; 35(7):1702-5. PubMed ID: 1131828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potentiation of the antitumor activity of methotrexate by concurrent infusion of thymidine.
    Semon JH; Grindey GB
    Cancer Res; 1978 Sep; 38(9):2905-11. PubMed ID: 679199
    [No Abstract]   [Full Text] [Related]  

  • 5. New approaches to cancer chemotherapy with methotrexate.
    Frei E; Jaffe N; Tattersall MH; Pitman S; Parker L
    N Engl J Med; 1975 Apr; 292(16):846-51. PubMed ID: 1078714
    [No Abstract]   [Full Text] [Related]  

  • 6. Enhancement of the therapeutic effectiveness of methotrexate and protection of normal proliferating tissues with purines and pyrimidines.
    Harrap KR; Taylor GA; Browman GP
    Chem Biol Interact; 1977 Jul; 18(1):119-28. PubMed ID: 302148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation versus rescue of antimetabolite toxicity by salvage metabolites administered by continuous infusion.
    Grindey GB; Semon JH; Pavelic ZP
    Antibiot Chemother (1971); 1978; 23():295-304. PubMed ID: 306219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thymidine 5'-O-pivaloate. A prodrug derivative of thymidine with potential applications in high-dose methotrexate therapy.
    Ensminger WD; Rosowsky A
    Biochem Pharmacol; 1979 May; 28(9):1541-5. PubMed ID: 475865
    [No Abstract]   [Full Text] [Related]  

  • 9. Some observations on the reversibility of methotrexate toxicity in normal proliferating tissues.
    Straw JA; Talbot DC; Taylor GA; Harrap KR
    J Natl Cancer Inst; 1977 Jan; 58(1):91-7. PubMed ID: 299894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved therapeutic index with high-dose methotrexate: comparison of thymidine-purine rescue with citrovorum factor rescue in mice.
    Samuels LL; Straw JA
    Cancer Res; 1984 Jun; 44(6):2278-84. PubMed ID: 6609764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methotrexate revisited.
    Frei E
    Med Pediatr Oncol; 1976; 2(3):227-41. PubMed ID: 790144
    [No Abstract]   [Full Text] [Related]  

  • 12. Reversal of methotrexate inhibition of colony growth of L1210 leukemia cells in semisolid medium.
    Nederbragt H; Uitendaal MP; van der Grint L; Leyva A; Pinedo HM
    Cancer Res; 1981 Mar; 41(3):1193-8. PubMed ID: 6970074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of high-dose methotrexate with leucovorin rescue therapy in the L1210 leukemia and sarcoma 180 murine tumor models.
    Sirotnak FM; Moccio DM; Dorick DM
    Cancer Res; 1978 Feb; 38(2):345-53. PubMed ID: 304375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of high-dose methotrexate with thymidine and low-dose leucovorin.
    Bruno S; Grindey G; Zakrzewski S; Priore R; Kinahan J; Moayeri H; Ledesma E; Mittelman A; Creaven P
    Cancer Res; 1982 Nov; 42(11):4824-6. PubMed ID: 6982097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical modulation by thymidine and hypoxanthine of sequential methotrexate-5-fluorouracil synergism in murine L1210 cells.
    Piper AA; Nott SE; Mackinnon WB; Tattersall MH
    Cancer Res; 1983 Nov; 43(11):5101-5. PubMed ID: 6616448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of concomitant infusion of thymidine and inosine on methotrexate activity in normal and P388-bearing mice.
    Uitendaal MP; Schornagel JH; Leyva A; Pinedo HM
    Eur J Cancer Clin Oncol; 1984 Dec; 20(12):1527-32. PubMed ID: 6542016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of "early" thymidine/inosine protection as an adjunct to methotrexate therapy.
    Eleff M; Franks PE; Wampler GL; Collins JM; Goldman ID
    Cancer Treat Rep; 1985; 69(7-8):867-74. PubMed ID: 2410122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. l-5-formyltetrahydrofolate and l-5-methyltetrahydrofolate rescue in L1210 leukemia treated with high methotrexate doses.
    Simile MM; DeMiglio MR; Nufris A; Pascale RM; Muroni MR; Feo F
    Res Commun Chem Pathol Pharmacol; 1993 Aug; 81(2):251-4. PubMed ID: 8210704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The antileukemic effectiveness of 5-fluorouracil and methotrexate in the combination chemotherapy of advanced leukemia L1210 in mice.
    Kline I; Venditti JM; Mead JA; Tyrer DD; Goldin A
    Cancer Res; 1966 May; 26(5):848-52. PubMed ID: 5934795
    [No Abstract]   [Full Text] [Related]  

  • 20. High-dose methotrexate therapy with citrovorum factor: a pharmacologic perspective in murine tumor models.
    Sirotnak FM; Donsbach RC; Dorick DM; Moccio DM
    Cancer Treat Rep; 1977 Jul; 61(4):565-74. PubMed ID: 301778
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.